๐ฐ Batch P&L โ Reta 60mg (PO-37066)
Reconciled view of the Amo Retatrutide batch. Source: PO-37066 ยท SKU-RETA-60MG.
Costs โ RM4,284
| Item | RM |
|---|---|
| USDT (peptides) | 3,922.55 |
| TRX (gas) | 52.00 |
| Wise fees | 27.16 |
| Peptide subtotal | 4,001.71 |
| BAC water | 87.96 |
| Insulin syringes | 180.43 |
| Alcohol swabs | 15.00 |
| Total landed (incl consumables) | โ 4,284 |
Sales to date โ RM5,780
| Item | Qty | RM |
|---|---|---|
| Reta 60mg @ RM400 | 14 | 5,600 |
| GHK-Cu @ RM90 | 2 | 180 |
| Total | 5,780 |
Result
- Profit to date: RM1,496 (RM5,780 โ RM4,284). โ ties to your figure.
- The whole batch cost is already recovered โ and 16 Reta vials remain in stock.
- Those 16 vials = RM6,400 retail still to come, at ~RM258/vial loaded margin โ ~RM4,100 additional profit if all sell.
- Projected full-batch profit: ~RM5,600 once the remaining 16 sell.
Two open reconciliation items
- USD order ($629 โ RM2,526) vs USDT paid (RM3,922.55) โ confirm what the extra ~RM1,400 covered.
- GHK-Cu sales sit against the Reta batch cost here; book GHKโs own COGS separately at month-close for a clean per-SKU margin.